Walleye Capital’s Lyell Immunopharma LYEL Stock Holding History

Walleye Capital’s Portfolio LYEL Stock Details LYEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$147K	Sell	10,451 -11,756	-53%	-$213K	﹤0.01%	3690
2026 Q1	$445K	Buy	+22,207	New	+$519K	﹤0.01%	2757
2025 Q3	–	Sell	-29,230	Closed	-$258K	–	4848
2025 Q2	$258K	Buy	+29,230	New	+$266K	﹤0.01%	3175
2023 Q1	–	Sell	-2,939	Closed	-$204K	–	4188
2022 Q4	$204K	Sell	2,939 -8,112	-73%	-$806K	﹤0.01%	2037
2022 Q3	$1.62M	Buy	+11,051	New	+$1.5M	0.03%	671
2022 Q2	–	Sell	-8,047	Closed	-$813K	–	2563
2022 Q1	$813K	Buy	8,047 +7,447	+1,241%	+$902K	0.02%	737
2021 Q4	$93K	Buy	+600	New	+$134K	﹤0.01%	1702

Other funds holding LYEL

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

CUAMC

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

SCM

Sterling Capital Management Charlotte, North Carolina $5.9B AUM 29.63% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Walleye Capital's LYEL Position: Q2 2026 in Review

Walleye Capital reduced its Lyell Immunopharma (LYEL) stake by 53% in Q2 2026, selling an estimated $213K and leaving 10,451 shares worth $147K. The position accounts for ﹤0.01% of the portfolio, ranked #3690.

Walleye Capital first reported a position in LYEL in Q4 2021 and has held it in 7 quarters since. The position peaked at $1.62M in Q3 2022. 8 funds tracked by Wall St. Rank hold LYEL as of Q2 2026.

Walleye Capital held 10,451 shares of Lyell Immunopharma worth $147K as of Q2 2026.
Walleye Capital sold 11,756 Lyell Immunopharma shares in Q2 2026, an estimated $213K.
Lyell Immunopharma made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #3690 holding.
Walleye Capital first reported a position in Lyell Immunopharma in Q4 2021 and has held it in 7 quarters since.
Walleye Capital's Lyell Immunopharma position peaked at $1.62M in Q3 2022.
8 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.